Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Palatin Technologies reports revenue challenges but advances pipeline programs

Palatin Technologies faced revenue challenges in Q3 2024 but showcased strengths in pipeline advancements and positive clinical results.
The company's financial performance improved despite increased operating expenses, with a focus on expanding clinical programs and enhancing drug profiles.
While facing cash utilization concerns and upcoming study expenses, Palatin remains optimistic about its progress and future milestones.

Palatin Technologies reports Q4 loss, progresses in ocular treatments

Palatin Technologies navigated Q4 2024 with a focus on cost reduction and asset sales, impacting revenue and expenses.
Despite financial challenges, the company's progress in ocular programs and pipeline development showcases strategic advancements.
Opportunities lie in leveraging asset sale proceeds, advancing clinical programs, and addressing funding needs for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRANBURY, N.J., Nov. 15, 2021 /PRNewswire/ -- Palatin Technologies, Inc., (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced results for its first fiscal quarter ended September 30, 2021.

Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update

CRANBURY, N.J., Nov. 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2022 operating results on Monday, November 15, 2021, before the open of the U.S. financial markets.

Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021

CRANBURY, N.J., Oct. 22, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced that its pre-clinical diabetic retinopathy poster demonstrating the positive effects of melanocortin agonists for retinal inflammation was awarded a Top 10 Posters designation at the  American Society of Retina Specialists (ASRS) 2021 Annual Meeting.

Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2021 Results - Earnings Call Transcript

CRANBURY, N.J., Sept. 29, 2021 /PRNewswire/ -- Palatin Technologies, Inc., (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced results for its fourth quarter and fiscal year ended June 30, 2021.

Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update

CRANBURY, N.J., Sept. 27, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the presentation of the protective effects of melanocortin 1 receptor agonists PL8331 and PL9654 in mouse models of retinopathy, at the 2021 Annual Meeting of the American Society of Retina Specialists (ASRS), being held virtually October 8-12, 2021.

Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

CRANBURY, N.J., Sept. 24, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September 29, 2021, before the open of the U.S. financial markets.

Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021

CRANBURY, N.J., Sept. 15, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced a featured speaker presentation and two poster presentations at the upcoming TIDES USA hybrid conference in Boston, Massachusetts on September 20-23, 2021.

Palatin to Present Peptides Platform at the TIDES USA Conference

CRANBURY, N.J., Sept. 13, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D.

Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual Conference

CRANBURY, N.J., July 22, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that Carl Spana, PhD, President and CEO of Palatin, presented today at the Eyecelerator@ASCRS Conference in Las Vegas, NV.

Palatin Announces Presentation at the Eyecelerator@ASCRS Conference

CRANBURY, N.J., July 8, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened on June 8, 2021 and was adjourned to July 8, 2021, has been adjourned until August 6, 2021 at 9:00 a.m.

Palatin Announces Adjournment of Annual Meeting of Stockholders

Antares Pharma

GT Biopharma Inc

ObsEva

Ocugen, Inc.

Odonate Therapeutics

Seelos Therapeutics

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

7 Penny Stocks For Your Watch List This Week If You Like Biotech In July

Phunware Inc

Transocean

SeaChange International

Seanergy Maritime Hlds

Uranium Energy

Ur-Energy

What do you need to know about trading penny stocks in 2021? Here's 3 tips and 7 small-caps to watch The post What Penny Stocks Investors Need to Know in July and 7 Stocks to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What Penny Stocks Investors Need to Know in July and 7 Stocks to Watch

Palatin Technologies Inc (NYSE: PTN) has completed an End-of-Phase 2 (EOP2) meeting with the FDA for PL9643 for the treatment of dry eye disease (DED). Palatin remains on track to initiate the Phase 3 program in DED patients during Q4 of 2021, with data readout expected in 2H of 2022.

Palatin Technologies Stock Moves Higher After Outlining Plans For Dry Eye Disease Treatment

CRANBURY, N.J., June 29, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced the completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for PL9643 for the treatment of dry eye disease (DED).

Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease

CRANBURY, N.J., June 28, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced the strengthening of its senior leadership team with three key executive management appointments: Michael B.

Palatin Announces New Additions to Its Senior Leadership Team

Palatin Technologies' (PTN) CEO Carl Spana on Q3 2021 Results - Earnings Call Transcript

CRANBURY, N.J., May 17, 2021 /PRNewswire/ -- Palatin (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced results for its third fiscal quarter ended March 31, 2021.

Palatin Reports Financial Results for the Third Fiscal Quarter of 2021 and Provides Corporate Update

CRANBURY, N.J., May 14, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that it will host a key opinion leader (KOL) webinar on melanocortin agonists for treating ocular indications, with a primary focus on PL9643, the Company's lead asset.

Palatin Hosting Key Opinion Leader Webinar in Role of Melanocortin Agonists in Inflammation and the Treatment of Ocular Indications

CRANBURY, N.J., May 13, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2021 operating results on Monday, May 17, 2021 before the open of the U.S. financial markets.

Palatin to Report Third Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on May 17, 2021

CRANBURY, N.J., May 4, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that the United States Patent and Trademark Office (USPTO) issued Notices of Final Determination and Requirement for Election on a patent term extension for two U.S. patents covering the Vyleesi® (bremelanotide injection) drug substance, U.S. patents 6,579,968 and 6,794,489.

Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection)

Aptinyx Inc

Bioline RX

Cyclerion Therapeutics Inc

Lineage Cell Therapeutics Inc

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week

CRANBURY, N.J., April 20, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two presentations of the Company's melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021.

Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

CRANBURY, N.J., March 5, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl...

Palatin Technologies to Participate in H.C. Wainwright Global Life Sciences Virtual Conference

Palatin Technologies' (PTN) CEO Carl Spana on Q2 2021 Results - Earnings Call Transcript

News for Palatin Technologies Stock (PTN)